The new generation weight-loss drug developed by the U.S. biotechnology company Metsera, Inc. (MTSR) demonstrated excellent ...

European technology stocks led sectoral declines, falling 1.9 percent. “Any bad news is being punished quite badly and tech ...

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) reported a rise in third-quarter revenue and earnings but surprised ...

Asian equities fell at the end of a volatile week marked by conflicting views, as investors balanced optimism over ...

Novo Nordisk A/S has again increased its offer for Metsera Inc. as its takeover battle with Pfizer Inc. for the obesity ...

EUROPEAN stocks fell on Thursday, dragged by technology stocks that came under fresh selling pressure while investors ...

Pfizer and Novo Nordisk are engaged in an intense bidding war for Metsera, a biotech company known for developing obesity drugs. Novo has raised its offer above Pfizer's $10 billion bid, escalating ...

On this week’s episode of "The Readout LOUD," melodrama at the top of the FDA and the latest on the Pfizer-Novo Nordisk ...

The Pfizer and Novo Nordisk battle for obesity drug developer Metsera intensified on Thursday after a fresh round of ...

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s amended proposal to acquire Metsera, the State of Texas’ attempt to block Kenvue’s planned dividend payment, and how data and AI are ...

Danish company is battling with Pfizer for US biotech as they seek edge in growing market for weight-loss drugs ...

In Episode 28, Miroslav Gasparek, Sensible; Lizzy Lawrence, STAT; and Joe Lewis, Deloitte, go behind the headlines.